Boston Partners acquired a new position in Encompass Health Corporation (NYSE:EHC - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,300,859 shares of the company's stock, valued at approximately $158,053,000. Boston Partners owned 1.33% of Encompass Health at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of EHC. Ancora Advisors LLC bought a new position in shares of Encompass Health in the 2nd quarter worth approximately $10,639,000. Canada Pension Plan Investment Board purchased a new position in shares of Encompass Health in the second quarter worth approximately $7,723,000. VELA Investment Management LLC grew its position in Encompass Health by 53.6% during the second quarter. VELA Investment Management LLC now owns 48,991 shares of the company's stock valued at $4,952,000 after buying an additional 17,105 shares during the period. Oppenheimer Asset Management Inc. bought a new stake in Encompass Health during the second quarter valued at approximately $2,620,000. Finally, Deutsche Bank AG purchased a new stake in Encompass Health during the second quarter valued at approximately $1,285,000. Hedge funds and other institutional investors own 97.25% of the company's stock.
Encompass Health Stock Performance
Encompass Health stock opened at $132.05 on Friday. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 0.73. Encompass Health Corporation has a twelve month low of $92.77 and a twelve month high of $143.90. The company's 50-day moving average price is $127.94 and its 200-day moving average price is $112.87. The company has a market cap of $12.96 billion, a PE ratio of 20.63, a price-to-earnings-growth ratio of 2.34 and a beta of 0.83.
Encompass Health (NYSE:EHC - Get Free Report) last announced its earnings results on Wednesday, October 28th. The company reported $1.52 EPS for the quarter, topping analysts' consensus estimates of $1.36 by $0.16. Encompass Health had a return on equity of 18.35% and a net margin of 10.17%. The firm had revenue of $1.61 billion during the quarter, compared to analysts' expectations of $1.60 billion. During the same quarter in the previous year, the business earned $1.23 EPS. The company's quarterly revenue was up 8.9% on a year-over-year basis. On average, equities research analysts forecast that Encompass Health Corporation will post 6.28 EPS for the current fiscal year.
Encompass Health Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, January 15th. Investors of record on Monday, January 4th will be paid a dividend of $0.21 per share. The ex-dividend date of this dividend is Monday, January 4th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.6%. Encompass Health's payout ratio is currently 13.12%.
Key Stories Impacting Encompass Health
These are some of the EHC stories that stood out recently:
- Positive Sentiment: Zacks Research increased estimates for multiple periods, including FY2026 EPS to $6.24, FY2027 to $6.65, and FY2028 to $7.44. It also lifted several quarterly forecasts, including Q2 2028 to $1.94 per share. These upward revisions indicate stronger analyst expectations for earnings growth. Encompass Health analyst estimates
- Neutral Sentiment: A separate Zacks article described EHC as a long-term value-stock candidate, but the provided summary gives no specific valuation data or new company developments to gauge the claim’s immediate impact. Why Encompass Health is a Top Value Stock for the Long-Term
Insider Buying and Selling
In related news, EVP John Darby sold 4,858 shares of the stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $121.09, for a total value of $588,255.22. Following the sale, the executive vice president directly owned 75,041 shares of the company's stock, valued at $9,086,714.69. This represents a 6.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.80% of the company's stock.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on EHC. KeyCorp lifted their price target on shares of Encompass Health from $147.00 to $150.00 and gave the stock an "overweight" rating in a research note on Friday, October 30th. Wall Street Zen raised Encompass Health from a "hold" rating to a "buy" rating in a report on Saturday, October 31st. Mizuho set a $155.00 target price on Encompass Health in a research report on Monday, November 2nd. Weiss Ratings raised shares of Encompass Health from a "buy (b-)" rating to a "buy (b)" rating in a report on Thursday, October 8th. Finally, Barclays boosted their target price on shares of Encompass Health from $144.00 to $151.00 and gave the stock an "overweight" rating in a report on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $154.25.
Read Our Latest Analysis on EHC
Encompass Health Company Profile
(
Free Report)
Encompass Health Corporation is a U.S. healthcare provider focused on inpatient rehabilitation. The company operates rehabilitation hospitals that offer specialized care for people recovering from conditions such as strokes, brain and spinal cord injuries, orthopedic conditions, and other illnesses or injuries. Its hospitals provide coordinated rehabilitation services, including physical, occupational, and speech therapy, alongside medical care. Encompass Health serves patients through facilities across the United States.
Featured Stories
Want to see what other hedge funds are holding EHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Encompass Health Corporation (NYSE:EHC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Encompass Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Encompass Health wasn't on the list.
While Encompass Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.